Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)-Reference-Cited by-同舟云学术

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)

Published:2005-01 Issue:1 Volume:16 Page:90-96
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Gervais R.,Ducolone A.,Breton J.-L.,Braun D.,Lebeau B.,Vaylet F.,Debieuvre D.,Pujol J.-L.,Tredaniel J.,Clouet P.,Quoix E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/16/1/90/435009/mdi018.pdf

Reference27 articles.

1. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Cancer Base No 5;Ferlay,2001

2. Chemotherapy of lung cancer;Ihde;N Engl J Med,1992

3. Cancer Statistics, 2004;Jemal;CA Cancer J Clin,2004

4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials;Non-small Cell Lung Cancer Collaborative Group;BMJ,1995

5. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline Update 2003;Pfister;J Clin Oncol,2004

Cited by 584 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms;Die Onkologie;2024-08-15

2. TRKing down drug resistance in NTRK fusion‐positive cancers^†;The Journal of Pathology;2024-07-29

3. Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP;Journal of Pathology and Translational Medicine;2024-07-15

4. Introduction and impact of routine whole genome sequencing in the diagnosis and management of sarcoma;British Journal of Cancer;2024-07-12

5. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents;British Journal of Cancer;2024-06-20